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Background: Many children with asthma do not have sufficient asthma control, which leads to increased
healthcare costs and productivity loss of parents. One of the causative factors are adherence problems. Effective
interventions improving medication adherence may therefore improve asthma control and reduce costs.
A promising solution is sending real time text-messages via the mobile phone network, when a medicine is about
to be forgotten. As the effect of real time text-messages in children with asthma is unknown, the primary aim of
this study is to determine the effect of a Real Time Medication Monitoring system (RTMM) with text-messages on
adherence to inhaled corticosteroids (ICS). The secondary objective is to study the effects of RTMM on asthma
control, quality of life and cost-effectiveness of treatment.
Methods: A multicenter, randomized controlled trial involving 220 children (4–11 years) using ICS for asthma.
All children receive an RTMM-device for one year, which registers time and date of ICS doses. Children in the
intervention group also receive tailored text-messages, sent only when a dose is at risk of omission. Primary
outcome measure is the proportion of ICS dosages taken within the individually predefined time-interval.
Secondary outcome measures include asthma control (monthly Asthma Control Tests), asthma exacerbations,
healthcare use (collected from hospital records, patient reports and pharmacy record data), and disease-specific
quality of life (PAQLQ questionnaire). Parental and children’s acceptance of RTMM is evaluated with online focus
groups and patient questionnaires. An economic evaluation is performed adopting a societal perspective, including
relevant healthcare costs and parental productivity loss. Furthermore, a decision-analytic model is developed in
which different levels of adherence are associated with clinical and financial outcomes. Also, sensitivity analyses are
carried out on different price levels for RTMM.
Discussion: If RTMM with tailored text-message reminders proves to be effective, this technique can be used in
daily practice, which would support children with suboptimal adherence in their asthma (self)management and in
achieving better asthma control and better quality of life.
Trial registration: Netherlands Trial Register NTR2583.
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Asthma is the most common chronic childhood disease
in industrialised countries and its prevalence has been
increasing in the past years [1,2]. As in adults, asthma in
children is associated with more hospitalisations, a de-
creased quality of life [3,4] and a substantial economic
burden [5]. Children themselves report several negative
consequences of asthma: feeling ill, limitations in peer
interactions and medication annoyances [6]. Other prob-
lems include limited sports participation and school at-
tendance [7]. These phenomena indicate that many
children do not have sufficient asthma control, in spite
of the availability of effective maintenance therapy in the
form of inhalation corticosteroids (ICS). In a Dutch
study 55% of the children with doctor-diagnosed asthma
had insufficient control [8]. Poor adherence to ICS is an
important risk factor for insufficient asthma control
[9,10]. Studies show that adherence to ICS ranges from
40 to 70% [11-17].
The disruptive effect of non-adherence on asthma
treatment implies that solutions are needed for improv-
ing adherence. Up to now, many interventions focus on
education of parents and children. Review studies show
that such educational interventions can result in a lower
risk of hospital admissions but the effect on other outcomes
is less clear [18,19]. A meta review on adherence showed
that although education seems plausible for explaining
adherence, the effects of educational interventions aimed to
improve adherence were yet unclear [20]. A promising,
yet complex, approach is to combine several interventions,
e.g. improving the patient-doctor relationship, training the
doctor’s communication skills and simplifying asthma med-
ication [21].
Lately, information and communication technology
(ICT)-solutions have been proposed to improve adherence
and their effectiveness has been shown [22-24]. Examples
are internet-based monitoring of asthma symptoms [25]
and audiovisual reminding to take asthma medication [26].
Reminding patients through the sending of text-messages is
a simple method with low intrusiveness and relatively low
costs [27]. Text-message reminding might be especially
suitable for unintentionally non-adherent patients, e.g. pa-
tients who forget to take their medication [28]. Several sys-
tematic reviews have shown that text-messaging is effective
in the improvement of health outcomes or in changing
health behaviour [24,29,30]. Examples include improved
blood glucose levels in obese type 2 diabetes patients [31],
higher level of physical activity [32], higher smoking cessa-
tion rates [33,34] and improved self-efficacy in young pa-
tients with diabetes type 1 [35]. In adult asthma patients
positive results of daily text-message alerts have been
reported as well: adherence to inhaler medication was 18%
higher in patients receiving a 12 week intervention with
text-message reminders [36].A concern with repetitive sending of text-messages be-
fore every intake may be that patients get accustomed to
receiving reminders leading to wearing-off of the adher-
ence improving effect. To avoid this “alert-fatigue”, a
more sophisticated approach is needed for optimal and
enduring adherence improvement. Such an approach
may consist of sending time-tailored text-message re-
minders that are sent only if a drug dose is at risk of
omission. This technique needs the use of Real Time
Medication Monitoring (RTMM), which is an adaptation
of the Medication Event Monitoring System (MEMS).
Like MEMS, RTMM uses an electronic medication dis-
penser that records the date and time the dispenser is
opened. MEMS has proven to provide objective and reli-
able data of adherence and it has been used to measure
medication adherence of various patient populations
[37,38]. RTMM delivers the same type of data but, as
opposed to MEMS, RTMM registers medication intake
data in real time at a central data-server. This real time
information is directly available, which enables sending
text-messages to patients who are at risk of missing a
dose of their medication.
The effect of sending time-tailored text-messages has
not been studied extensively before. One randomized
controlled trial for oral medication in adult diabetic pa-
tients has shown RTMM to be effective [39]. Also, pre-
liminary results of a study in HIV-infected adults using
RTMM show that patients receiving tailored text-message
reminders improve adherence to antiretroviral therapy
as well as rates of viral suppression [40]. The application
of RTMM in children using inhalation medication has
not been studied before and therefore needs further inves-
tigation. Since enhancement of inhalation therapy with
RTMM is still an innovative and expensive technique,
RTMM equipment and software are only available for re-
search purposes. Before this technique can be further de-
veloped into a design suitable for regular care, more data
are needed on cost-effectiveness and patient acceptance.
Therefore, in this study we investigate the impact of
RTMM with time-tailored text-message reminding on ad-
herence to ICS in children with asthma. Secondary aim is
to determine the effect of RTMM on asthma-control. Fi-
nally, cost-effectiveness and patient acceptance of RTMM
are studied.
Methods/design
Design
This study is a one year, multicenter, randomized con-
trolled trial in children who use ICS for asthma. All chil-
dren receive an RTMM-device which registers time and
date of administered ICS doses. Children in the inter-
vention group receive “time-tailored” text–messages that
are only sent when a dose is at risk of omission. Patients
in the control group do not receive such text-messages.
Figure 1 Patient section.
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The medical ethics committee of the Erasmus Medical
Center has approved the study protocol (protocol number
MEC-2011-143, Netherlands Trial Registry code NTR2583,
www.trialregister.nl).
Study data are coded in order to guarantee privacy of
participants. Before entering the study, all participants
are asked for written informed consent.
Participants
Patients are recruited from five outpatient clinics in the
Netherlands: St Lucas Andreas Hospital, Academic Medical
Center, BovenIJ Hospital (all in Amsterdam), Erasmus MC
(in Rotterdam) and Groene Hart Ziekenhuis (in Gouda).
The inclusion criteria for participants are:
• Age at start of the study is 4 to 11 years. Children
aged 12 years or older tend to show a more individual
medication behaviour, with a smaller role for parents
compared to younger children. Also, the Asthma
Control Test, a questionnaire for measuring asthma
control, was only validated for children aged 4 to11
years [41,42].
• Doctor diagnosed asthma for at least six months. This
criterion aims to exclude patients with transient
wheezing e.g. due to viral respiratory tract infections.
Shortly after the diagnosis of asthma, patients may also
be better motivated for treatment than in later stages of
their disease. That is why we have chosen to aim for
patients with chronic asthma. These are also the
patients who are on maintenance therapy with ICS.
• ICS use for at least three months. In the first period of
ICS use, adherence rates may be higher than normal.
Therefore, only patients with chronic ICS use are
included [10].
• Use of a pressurized metered dose inhaler (pMDI).
The RTMM-devices used for electronic adherence
measurement are only compatible with pMDIs.
Children using ICS with nebulizers or dry powder
inhalers can therefore not be included.
• Use of fluticasone, fluticasone/salmeterol or
beclomethasone. The experimental RTMM-devices have
been developed to accommodate only fluticasone
(FlixotideW), fluticasone/salmeterol (SeretideW) or
beclomethasone (QVARW) inhalers. Children using
other types of ICS can therefore not be included.
Unless clinically indicated, childrens’ asthma medication
will not be changed to fit this inclusion criterium.
• At least one parent/caregiver has a mobile phone. In
the intervention group real-time text-message
reminders are sent via the mobile telephone network.
Also, alerts for low battery status of the RTMM-devices
are automatically communicated with text-message
reminders.We aim to include 44 children per hospital into the
study. From the hospital administrations of each partici-
pating hospital, records are randomly selected of chil-
dren aged 4–11 years and diagnosed with asthma at
least 6 months ago. After verification of the other inclu-
sion criteria, a patient information leaflet is handed out
or sent to the parents of the potential participants. Par-
ents are contacted and invited to visit the paediatric out-
patient department for an intake interview. In case of
participation, at least one of the childs’ parents has to
give written informed consent. If a hospital is unable to
include the required number of patients, they will be
recruited from one of the other participating hospitals.
Children are randomly assigned to the intervention
group or the control group. We use block randomization
per hospital with blocks of 16 patients. Initially, physi-
cians, researchers, and patients are blinded for random-
isation. However, randomisation is unblinded after start
of the study period, when patients find out whether they
receive text-message reminders or not.
A flowchart of patient selection, randomisation and
data collection is shown in Figure 1.Intervention
All children, both in the intervention and in the control
group, receive an RTMM device for one year. ICS inhala-
tions are registered by the RTMM-device which operates
as follows: each time the pMDI is fired a data message
containing patient-identification and time and date of ad-
ministration is sent to the study database using the mobile
telephone network. In order to prevent incomplete regis-
tration caused by insufficient network connection, the
RTMM-device is designed to use two different networks:
the mobile data-network and the regular mobile telephone
network. If both networks are unavailable at the time of
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later moment.
Only in the intervention group, time-tailored text-
message reminders are sent to the parents and, if the
child has a mobile phone, also to the child, in order to
warn that a dose is at risk of being forgotten. Parents
and children are not always together, for example if chil-
dren are at school. As such, there may be a problem if
the child has missed its dose and is already at school when
the text-message is received by its parents. In that case, par-
ents will not be able to verify if the child takes its medica-
tion. To ensure that text-messages are sent before the child
goes to school (morning dose) or to bed (evening dose), a
text-message is sent automatically if no ICS dose has been
registered within 15 minutes after the planned time of in-
halation. Such a short time interval may be less important
when children are not at school, for example during week-
ends. For that reason, time intervals are individually defined
(‘time-tailored’) for each patient for each day of the week.
This is also thought to improve patient-acceptance of
RTMM, reducing the so called “alert fatigue”.
Patients in the intervention group who live in an area
with a very poor mobile network connection may occa-
sionally receive an unnecessary text-message reminder if
an ICS administration can not be reported to the RTMM-
database in time. When the RTMM-network connection is
re-established, the data message is sent. This phenomenon
is closely monitored during the study period.
Data collection
Outcome measures
The primary outcome measure is adherence to ICS, de-
fined as the proportion of all prescribed dosages taken
by the child within a six hour time-frame around the
planned time of inhalation, i.e. from 3 hours before until
3 hours after. This is a common measure for twice daily
dosing regimens [43-46]. In addition, we will look at other
time-frames, missed doses and extra doses. These data are
calculated from the RTMM data on ICS use, which are
collected as described earlier in the “intervention”-section.
Secondary outcome measures are asthma control, fre-
quency of asthma exacerbations, disease specific quality
of life, healthcare use for asthma and school/work ab-
sence. These data are also used for calculation of the
cost effectiveness of RTMM in children with asthma.
Asthma control is measured in several ways. The child-
hood Asthma Control Test (ACT) is filled out each month
during the entire study in order to avoid seasonal differ-
ences [47]. The ACT is a questionnaire validated for chil-
dren aged 4–11 years [41,42]. The ACT is a simple 7-item
questionnaire, which has been shown to be useful in the
detection of poorly controlled asthma. The ACT-score is
calculated by adding the scores of all items; the ACT-
score ranges from 0 to 27. The cut-off score is 19 points:19 points or less means uncontrolled asthma, 20 points or
more means controlled asthma. The ACT can also be used
for measuring changes in asthma control. The minimally
important difference between consecutive ACT scores is
3 points [48]: if two consecutive ACT-scores differ three
points or more, the improvement or deterioration of
asthma control is substantial and clinically relevant. In this
study, asthma control is also measured using the frequency
of asthma exacerbations and healthcare use. Pharmacy rec-
ord data retrieved from the community pharmacy, are
checked once at the end of the study period for high dose,
short term oral corticosteroid use indicating asthma exac-
erbations. These pharmacy record data are also screened
for new prescriptions of asthma medication, indicating a
recent visit to a physician. Finally, the pharmacy record
data are used to calculate medication costs.
Apart from screening pharmacy record data, healthcare
use is also collected at the start and end of the study period
by screening patient records and the hospital administra-
tion for visits to the outpatient clinic and for hospital ad-
missions. Healthcare use and asthma related absence from
school (child) or work (parent) are also assessed in a patient
interview every 3 months. Asthma-specific quality of life is
assessed by filling the standardized Paediatric Asthma
Quality of Life Questionnaire (containing 23 items with a
7 point scale per item) (PAQLQ(S)) at the beginning
and end of the study period [49]. The domains
include activities, asthma symptoms and emotional
function. The PAQLQ score ranges from 1 to 7 and
is calculated as the average score of all items in a specific
domain as well as an overall score. The PAQLQ can also be
used to measure changes in quality of life. The minimally
important difference in consecutive PAQLQ scores is 0.5.
This is the minimum difference between two consecutive
PAQLQ-scores that should be interpreted as a relevant
improvement or deterioration of asthma-specific quality of
life. A difference of 1 point indicates a moderate change
and 1.5 is considered a large change [50].
Co-variables
We collect data on several factors that may be associated
with adherence to medication, including age, gender, eth-
nicity (country of birth of child and parents), type of ICS
(fluticasone, fluticasone/salmeterol or beclomethasone),
ICS-dose, dosing frequency of ICS, type of asthma related
co-medication (betasympathicomimetics, antihistaminergic
agents, decongestives, antibiotics etc.), use of a spacer,
parental level of education, parental Dutch language skills
(assessed by investigators on a 5 point scale), smoking
habits of parents (at home), family stability (child lives
with both parents together / only with mother / only with
father / both parents alternatively) [9], family income, pro-
fessional occupation of parents, pets, mutations of asthma
medication during the study period, existing spirometry
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adverse events. Parental medication beliefs are measured
using the Beliefs about Medicines Questionnaire Specific
(BMQ Specific). This contains a scale for beliefs in the
necessity of ICS and one for concerns about long term
toxicity and disruptive effects of ICS. Both scales range
from 5 to 25, with higher scores indicating stronger beliefs
[51,52]. The data are collected from medical records
at the beginning and end of the study period. In
addition, at the beginning and end of the study period, and
each 3 months in between, parents are interviewed by
research assistants for collection of relevant data that can-
not be extracted from medical records or questionnaires.
Research assistants are trained by the research team before
taking patient interviews.
Acceptance of RTMM
Since this study is an early evaluation of a medical
innovation, we will pay special attention to the accep-
tance of RTMM using online focus groups (OFGs). These
OFG discussions provide a convenient and comfortable
way of joining group discussions and enable dialogue be-
tween participants who may not otherwise have spoken
with each other. Discussions in computer-based focus
groups produce the same quantity and quality of informa-
tion obtained from face-to-face focus groups and are
equally enjoyed by participants [53]. An additional advan-
tage of OFGs is the larger contribution of less talkative
participants in the discussion. The method also allows
participants to join the discussion from their home and atTable 1 Collection of outcome measures and co-variables in c
Elapsed time since inclusion (months) 0 1 2 3
Study visit/patient interview X X
Registry of patient characteristics X
Adherence to ICS (continuous Real
Time Medication Monitoring, RTMM)
X X X X
Asthma control in past month
(Asthma Control Test, ACT)
X X X X
Asthma control in past 3 months
(collecting spirometry data)
X X
Collecting data on healthcare use and
school/work absence in the past 3 months
X
Collecting number of visits and admissions
to hospital for asthma in the past 12 months
X
Screening public pharmacy dispensing data
from the past 12 months (measuring asthma
control, healthcare use and medication costs)
Medication Beliefs (Beliefs about
Medicines Questionnaire,BMQ)
X
Asthma specific quality of life in
past week (PAQLQ)
X
Patient acceptance of RTMM
(Online Focus Groups, OFGs)a convenient time. OFGs are cost- and time-efficient due
to the automatic and accurate capture of the discussion
data. Children’s familiarity with the internet further pleads
in favour of this methodology in our study. The OFGs are
conducted following recently developed guidelines for on-
line data collection [54].
In this study the OFGs are used to assess factors that
would positively or negatively influence acceptance of
RTMM and to capture more detailed information on
how children and parents manage RTMM use. Eight
children in the intervention group aged 9–11 years are
asked to participate in an OFG. For younger children,
eight parents are asked to participate in an OFG. Thus,
two focus groups are created: one for children and one
for parents. Participants are asked to respond anonym-
ously to questions introduced by the researcher and to
each others’ comments. Questions concern participants’
views on the usefulness and acceptability of specific
components of the intervention. The researcher acts as
moderator by regularly checking the postings and by
asking additional questions to clarify participants’ views.
The OFGs are carried out in the second half of the
follow-up period. Table 1 provides a chronologic over-
view of all data that are collected in this study.
Data monitoring
Data are initially collected on a case report form (CRF)
and on questionnaires (hard copy). After each patient
interview data are manually copied to a digital CRF. Data
entry errors are minimized by using multiple choicehronologic order
4 5 6 7 8 9 10 11 12
X X X
X X X X X X X X X
X X X X X X X X X
X X X
X X X
X
X
X
X
X X X X X X
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of entered data are checked by a second person. If data
entry errors are found, additional portions of 10% of the
data are checked until no errors are found within a por-
tion. Also, a periodic back-up of the study database of
each hospital is made and checked for missing data. Ac-
cess to the research databases is secured by passwords.
Changing the format of the study documentation or study
databases is restricted to the primary investigator. New
versions are distributed from the central study location.
Data analysis
The sample size calculation was based on the primary
outcome measure: adherence to ICS. We use the adher-
ence data from our observational study [15] in which ad-
herence to ICS was electronically measured with RTMM
in children (<12 years old) with asthma. In this dataset,
4 subgroups with different adherence patterns could be
distinguished: patients with very poor adherence (≤5%),
poor adherence (mean 34%), good adherence (mean
78%) and excellent adherence (≥95%). We assumed that
patients with very poor adherence would not show any
relevant improvement, since it is likely that they deliber-
ately stopped taking ICS. The adherence rate in this
group is not likely to be improved by the text-message
intervention. The group with excellent adherence is also
not expected to show improvement, since adherence is
already nearly 100%. Adherence in both intermediate
groups (poor, good adherence) is expected to improve
by 10-15%. This estimated effect size was based on an
adherence improvement reported in a systematic review
on the effect of (non-tailored) reminder systems on patient
adherence to treatment [55]. Since the time-tailored text-
message reminders used in our study are considered
potentially more effective, we estimated the improvement
at 15%.
Using these assumptions, we have simulated the ad-
herence data of the control and treatment groups. Since
the four adherence subgroups cannot be analyzed in one
single regression model, we used a mixture of regressions
(“mixture model”) in order to assess the effect of the inter-
vention. We also calculated levels of statistical power at
different group sizes. Requiring a power of at least 0.8 and
assuming an adherence improvement of 15%, we calcu-
lated that a group size of 110 per arm is needed to detect
the expected difference. Data analysis is based on an
intention-to-treat principle. All patients with a follow-up
of at least three months, regardless of whether they actu-
ally finish the intervention, are included in the analysis.
The two groups are compared for baseline characteristics.
Co-variables that may influence adherence levels, and
therefore may confound the effect of the text-message
intervention on adherence, are added to the multivariable
model. In addition, a sensitivity analysis is carried outusing a per-protocol approach. In this analysis the effect is
studies of patients who complete less than three months
of follow-up and of patients who appear to have stopped
using ICS early in follow-up (less than 1% of total pre-
scribed inhalations are administered during the complete
follow-up). Data are analysed with SPSS for Windows.
For calculation of the cost-effectiveness a prospective
economic evaluation from a societal perspective is per-
formed alongside the clinical trial. The one-year costs of
all relevant health care utilization are included as well
the direct non-healthcare costs and the costs of produc-
tivity losses when parent stay home to take care of their
children. Costs will be related to adherence, asthma con-
trol and asthma-specific quality of life to calculate the
following incremental cost-effectiveness ratios (ICERs):
1. Costs per 10% improvement in adherence
2. Costs per additional patient with minimal clinically
important improvement in asthma control
3. Costs per additional patient with the minimal
clinically important improvement in asthma quality
of life. The uncertainty around the ICERs will be
displayed on cost effectiveness-planes and cost-
effectiveness acceptability curves.
Subsequently, a decision-analytic model is developed
that includes different levels or forms of adherence and
the outcomes, both clinical and costs, attributed to each
level or form of adherence as well as different price
levels for RTMM. For the base-case, this model is filled
with estimates of the relationship between adherence on
the one hand and asthma control, symptoms, exacerba-
tions, quality of life and healthcare utilization on the
other hand. These estimates are obtained from the clin-
ical trial, where potential associations between adher-
ence and outcomes are studied. This model is used to
run extensive one-way and multivariate sensitivity ana-
lyses to simulate the anticipated benefits of improved
adherence in terms of health outcomes and costs.
Discussion
We designed a randomised controlled trial in children
aged 4 to 11 using inhaled corticosteroids (ICS) for asthma.
We will investigate the clinical and cost effectiveness of
an intervention with Real Time Medication Monitoring
(RTMM) with text-message reminders. Medication taking
behaviour is monitored on a real-time basis, enabling im-
mediate patient feedback through “time-tailored” text-
message reminders that are only sent if the ICS is at risk
of omission.
In this study, RTMM with text-message reminders is
used as an adherence improving intervention. Three cat-
egories of adherence-enhancing strategies have been de-
fined: enabling, consequence and stimulant [56]. Enabling
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ence, e.g. patient education and simplified medication reg-
imens. Consequence strategies aim to reinforce adherence
by providing incentives for acceptable adherence, e.g. ins-
tructing patients to maintain records of pill-taking or hav-
ing patients monitor blood pressure at home. Stimulant
strategies are aimed at prompting dose-taking. The RTMM
with text-message reminders used in this study, is a stimu-
lant strategy and therefore primarily targets unintentional
non-adherence, e.g. forgetting to take a dose. This could
limit the expected effect of our intervention, since adher-
ence to ICS may also be influenced by intentional factors,
like illness perceptions (perceived susceptibility and sever-
ity of the disease), the perceived benefits of treatment
and theoretical barriers to treatment (e.g. concerns about
(potential) side effects) [57]. However, RTMM with text-
message reminders may also diminish intentional non-
adherence by providing patients with feedback, while
appealing to a desire to appear adherent when use is scruti-
nized by an outside party [55]. Receiving information that
an inhalation is about to be missed, may also enable pa-
tients to adjust their medication taking behaviour, thus im-
proving self-efficacy and asthma related quality of life [58].
Strengths and limitations
A strength of this study is the use of RTMM as an ob-
jective and reliable method for adherence measurement.
This method provides minimal room for bias, e.g. by so-
cially acceptable patient response (patient self-report),
misjudgement of patient behaviour (adherence question-
naires) and overestimation of adherence based on phar-
macy refill data (refill rate, persistence) [13,59,60]. The
RTMM device has been designed as a small add-on to
the ICS inhaler. Since it does not need to be carried sep-
arately, it provides a patient-friendly way of measuring
and stimulating adherence to ICS. This multi-centre
study is the first to investigate RTMM with text-message
reminders in a large sample of children with asthma. It
is also the first to study the cost-effectiveness of RTMM
in asthma. More data on cost-effectiveness are needed
since the costs of this innovative technique are still sub-
stantial (approximately €750,= per patient per year) and
are keeping physicians from using it in daily clinical
practice. Health insurance companies also require more
data on cost-effectiveness before covering costs for ap-
plying RTMM in asthma therapy.
Although electronic monitoring such as Real Time
Medication Monitoring is considered more sensitive for
measuring non-adherence than other, subjective tools
for adherence measurement [13,61,62] the actual adher-
ence to ICS may still be overestimated. All participating
patients are aware that they are being observed, so they
may act more adherent than in average daily practice. A
common critique of electronic medication monitoringbased on the time and date the inhaler is fired, is that it
cannot be confirmed that the medication is actually
taken. Only drug assays can confirm ingestion. However,
studies comparing the sequence of medication events
with projected and periodically measured concentrations
of the drug in plasma, confirmed the validity of medica-
tion event monitors. Mismatches between medication
events and actual dosing were too rare to create substan-
tial differences between projected and actual concentra-
tions of the drug in plasma [63-66]. Another concern
with adherence measurement of ICS is the fact that reg-
istered doses may not have been administered correctly
due to poor inhalation technique. This may have a nega-
tive influence on the effectiveness of ICS therapy [67]
and therefore on asthma related quality of life and on pa-
tients’ motivation to adhere to therapy. This phenomenon
is considered evenly distributed within intervention and
control group, so we expect that the effect on the outcome
measures adherence to ICS and “asthma control” is lim-
ited. A potential limitation of this study is the high quan-
tity of outcome-measures and co-variables (Table 1). This
may provoke partial non-response, leading to missing data.
Another concern is the fact that both children using
fluticasone and those using a combination of fluticasone
and the long acting beta-agonist salmeterol are included
into this study. It is well known that co-inhalation of a
long acting beta-agonist causes bronchodilatation resulting
in a relief from asthmatic symptoms. This may be reward-
ing for the asthma patient, possibly resulting in a better
adherence. Besides, patients needing a combination of
fluticasone and salmeterol may have more severe asthma
than those who’s symptoms can be sufficiently controlled
by ICS alone and may therefore be better motivated to
adhere to their asthma therapy. To overcome this limita-
tion we collect data on the type of ICS (fluticasone or
fluticasone/salmeterol) as a co-variable, which enables us
to include it as a confounder in the multi-variable analysis
or to perform stratified analysis.
One of the inclusion criteria of this study is the use of
ICS for at least three months. This is verified by checking
medical records and by asking potential participants
which drugs are used for asthma. This procedure, how-
ever, does not account for patients who have stopped
using ICS without consulting a physician. If a part of the
patients that are not included for not using an ICS still
had an indication for taking ICS, they have a 0% adher-
ence rate. Patients who, on the other hand, are included
into the study, but in fact already have stopped using ICS,
also have a 0% adherence rate. Since these phenomena are
expected to be equally distributed among patients in the
intervention and control group, the only potentially rele-
vant effect is a decrease in statistical power. In order to
quantify the effect of the latter (patients, who stopped
using ICS but still enter the study) a sensitivity analysis is
Vasbinder et al. BMC Medical Informatics and Decision Making 2013, 13:38 Page 8 of 10
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prescribed doses are excluded.
It is expected that RTMM has most value in patients
with therapy resistant poor asthma control. In daily prac-
tice, it is often unclear whether the prescribed asthma
treatment is suboptimal (e.g. dose is too low, inconvenient
inhaler) or the treatment is adequate, but the patient does
not adhere to it. In the current study, however, we have
chosen not to make a pre-selection of patients with poor
asthma control or (suspected) non-adherence. Instead,
asthma control is measured during the entire follow up,
which enables us to investigate if poor asthma control
at baseline is associated with response to the RTMM
intervention.
It is crucial for correct sending of text-messages and
for correct adherence measurement that any changes in
mobile telephone (used for receiving text-message re-
minders), ICS dose, ICS dosing frequency and type of ICS,
is correct at any moment during the study period. To en-
sure this, patients are requested to inform the investiga-
tors about any relevant changes. In addition these data are
verified in the patient interview each three months of
the study period. If RTMM-devices are detected that have
not been actuated for more than a month, patients are
contacted once to check for technical failures. This inter-
vention is documented.
The trial-based cost-effectiveness analysis proposed here
aims to explicitly estimate the cost-effectiveness of RTMM.
However, at this early stage of development of RTMM with
text-message alerting, adherence in stead of asthma control
was used as the primary outcome measure. Therefore, the
trial may not allow definite conclusions on the impact of
this intervention on the cost of asthma treatment. Hence,
we will apply appropriate decision-analytic modelling tech-
niques to simulate the anticipated benefits of improved ad-
herence. Such a model needs to relate the different levels
of exposure to ICS to levels of asthma control. A model
like that allows extensive sensitivity analyses on both clin-
ical outcomes and costs that are attributed to each level of
adherence.
Conclusion
RTMM with text-message reminders has the potential to
support non-adherent patients in improving their asthma
(self )management and in achieving better asthma control
and better quality of life. RTMM could also provide physi-
cians with the right information to treat patients who have
poorly controlled asthma despite ICS therapy. Additional
evidence on the (cost) effectiveness of this innovative ad-
herence improving strategy would contribute to making it
available for use in daily clinical practice.
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